Zobrazeno 1 - 10
of 208
pro vyhledávání: '"P Soelberg-Sorensen"'
Autor:
Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, on behalf of the MESEMS study group
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodege
Externí odkaz:
https://doaj.org/article/cecb42ab3b814fa7b6f5dace14d6516b
Autor:
Melinda Magyari, Per Soelberg Sorensen
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvi
Externí odkaz:
https://doaj.org/article/12cf0e8a8a2a4be7b5470069d6428842
Autor:
Per Soelberg Sorensen, Finn Sellebjerg
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Whereas drugs used for maintenance/escalation therapy do not maintain their beneficial effect after cessation of therapy, some new highly effective therapies can show prolonged treatment effects after a short treatment course. Such therapies have bee
Externí odkaz:
https://doaj.org/article/7d76e05f1d4f40298ec93e7e4e315f01
Autor:
Giancarlo Comi, Stuart Cook, Kottil Rammohan, Per Soelberg Sorensen, Patrick Vermersch, Abidemi K. Adeniji, Fernando Dangond, Gavin Giovannoni
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background The CLARITY and CLARITY Extension studies demonstrated that treatment of relapsing–remitting multiple sclerosis (RRMS) with cladribine tablets (CT) results in significant clinical improvements, compared with placebo. This paper presents
Externí odkaz:
https://doaj.org/article/c907d17b8399434aaea854c3ecaf40ce
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Delphine Bachelet, Signe Hässler, Cyprien Mbogning, Jenny Link, Malin Ryner, Ryan Ramanujam, Michael Auer, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Clemens Warnke, Kathleen Ingenhoven, Dorothea Buck, Verena Grummel, Andy Lawton, Naoimh Donnellan, Agnès Hincelin-Mery, Dan Sikkema, Marc Pallardy, Bernd Kieseier, Bernard Hemmer, Hans Peter Hartung, Per Soelberg Sorensen, Florian Deisenhammer, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, Philippe Broët, ABIRISK Consortium
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0162752 (2016)
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospecti
Externí odkaz:
https://doaj.org/article/f42ed773756e4b9bb482310f2683d0bf
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usag
Externí odkaz:
https://doaj.org/article/7a86d2e3d45d4d59aa40968fe384f1e9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Per Soelberg Sorensen
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 1 (2008)
The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-β). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller pro
Externí odkaz:
https://doaj.org/article/475a1e4ab87a4a059c85587e73e2ef07
Autor:
Gavin Giovannoni, B. Keller, Kottil Rammohan, Stuart D. Cook, Patrick Vermersch, P Soelberg-Sorensen, E. Verdun di Cantogno
Publikováno v:
Journal of the Neurological Sciences. 405:177-178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8448a9fb55036c6571cbb7e92109ae8
https://doi.org/10.1016/j.jns.2019.10.1122
https://doi.org/10.1016/j.jns.2019.10.1122